Antengene Corporation Limited and Hansoh Pharmaceutical Group Company Limited announced the entrance into a collaboration agreement between Antengene and Hansoh Pharma for the commercialization of XPOVIO® in the mainland of China. Under the terms of the agreement, Antengene will continue to be responsible for research and development, regulatory approvals and affairs, product supply, and distribution of XPOVIO®, while Hansoh Pharma will be exclusively responsible for commercialization of XPOVIO® in the mainland of China. Antengene will receive up to RMB 200 million of upfront payments, RMB 100 million of which shall be received upon signing, and pursuant to the Agreement and subject to the terms and conditions thereof, Antengene shall be eligible to receive up to RMB 100 million of the remaining upfront payments, and up to RMB 535 million in milestone payments from Hansoh Pharma.

Antengene will continue to record revenues from sales of XPOVIO® in the mainland of China and Hansoh Pharma will charge a service fee to Antengene.